-+ 0.00%
-+ 0.00%
-+ 0.00%

Ardelyx Presents Real-World Data Showing Significant Reduction In GI-Related Healthcare Resource Utilization After IBSRELA Initiation, At ACG 2026 Annual Meeting

Benzinga·10/12/2026 12:09:38
Listen to the news

Ardelyx, Inc. (NASDAQ:ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced results from a real-world analysis being presented at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting showing that gastrointestinal-related healthcare resource utilization (GI-HCRU) dropped significantly after adults with irritable bowel syndrome with constipation (IBS-C) started IBSRELA® (tenapanor). Ardelyx will also present data on how IBS-C symptom burden affects quality of life, along with the design and rationale of an ongoing Phase 3 study evaluating tenapanor in adults with chronic idiopathic constipation (CIC).